2-methoxy-3-benzyloxy-17β-(2-hydroxypropyl)estra-1,3,5(10)-triene | 1311311-75-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2-methoxy-3-benzyloxy-17β-(2-hydroxypropyl)estra-1,3,5(10)-triene
• 英文别名: 1-[(8S,9S,13R,14S,17R)-2-methoxy-13-methyl-3-phenylmethoxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]propan-2-ol
• CAS: 1311311-75-7
• 化学式: C₂₉H₃₈O₃
• 分子量: 434.619
• InChiKey: RVMVPVQTNLWCML-HGHGTCGNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methoxy-3-benzyloxy-17β-(2-hydroxypropyl)estra-1,3,5(10)-triene 在 sodium tetrahydroborate 、 palladium 10% on activated carbon 、 氨基磺酰氯 、 氢气 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基乙酰胺 、 异丙醇 为溶剂， 反应 54.0h， 生成 17β-(2-hydroxyropyl)-2-methoxy-3-O-sulfamoylestra-1,3,5(10)-triene
  参考文献：
  名称：

  Structure–Activity Relationships of C-17-Substituted Estratriene-3-O-sulfamates as Anticancer Agents

  摘要：

  The synthesis and antiproliferative activities of analogues of 2-substituted estradiol-3,17-O,O-bis-sulfamates (E2bisMATEs) are discussed. Modifications of the C-17 substituent confirm that an H-bond acceptor is essential for high activity; its optimal linkage to C-17 and the local environment in which it resides are defined. In the non-sulfamoylated series 17 beta-acyl substitution delivers 48b, the most potent compound identified to date. In the sulfamate series a number of permutations of linker and H-bond acceptor deliver excellent activity, with 55, 61, 65, 49a, and 49b proving especially promising. The in vivo potential of these compounds was explored in the NCI hollow fiber assay and also in a mouse Matrigel model of antiangiogenesis in which 49 and 55 show significant inhibitory activity.

  DOI：

  10.1021/jm200483x
• 作为产物：
  描述：

  3-(benzyloxy)-2-methoxyestra-1,3,5(10)-trien-17-one 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 二异丁基氢化铝 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 70.5h， 生成 2-methoxy-3-benzyloxy-17β-(2-hydroxypropyl)estra-1,3,5(10)-triene
  参考文献：
  名称：

  Structure–Activity Relationships of C-17-Substituted Estratriene-3-O-sulfamates as Anticancer Agents

  摘要：

  The synthesis and antiproliferative activities of analogues of 2-substituted estradiol-3,17-O,O-bis-sulfamates (E2bisMATEs) are discussed. Modifications of the C-17 substituent confirm that an H-bond acceptor is essential for high activity; its optimal linkage to C-17 and the local environment in which it resides are defined. In the non-sulfamoylated series 17 beta-acyl substitution delivers 48b, the most potent compound identified to date. In the sulfamate series a number of permutations of linker and H-bond acceptor deliver excellent activity, with 55, 61, 65, 49a, and 49b proving especially promising. The in vivo potential of these compounds was explored in the NCI hollow fiber assay and also in a mouse Matrigel model of antiangiogenesis in which 49 and 55 show significant inhibitory activity.

  DOI：

  10.1021/jm200483x

文献信息

• Structure–Activity Relationships of C-17-Substituted Estratriene-3-<i>O</i>-sulfamates as Anticancer Agents
  作者：Fabrice Jourdan、Mathew P. Leese、Wolfgang Dohle、Eric Ferrandis、Simon P. Newman、Surinder Chander、Atul Purohit、Barry V. L. Potter

  DOI：10.1021/jm200483x

  日期：2011.7.14

  The synthesis and antiproliferative activities of analogues of 2-substituted estradiol-3,17-O,O-bis-sulfamates (E2bisMATEs) are discussed. Modifications of the C-17 substituent confirm that an H-bond acceptor is essential for high activity; its optimal linkage to C-17 and the local environment in which it resides are defined. In the non-sulfamoylated series 17 beta-acyl substitution delivers 48b, the most potent compound identified to date. In the sulfamate series a number of permutations of linker and H-bond acceptor deliver excellent activity, with 55, 61, 65, 49a, and 49b proving especially promising. The in vivo potential of these compounds was explored in the NCI hollow fiber assay and also in a mouse Matrigel model of antiangiogenesis in which 49 and 55 show significant inhibitory activity.